Pilot Clinical Trial of Hedgehog Pathway Inhibitor GDC-0449 (Vismodegib) in Combination with Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma
This research output has an Altmetric Attention Score of 16. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 08 June 2021.
All research outputs
#2,845,255
of 33,212,904 outputs
Outputs from Clinical Cancer Research
#2,380
of 17,326 outputs
Outputs of similar age
#32,697
of 413,163 outputs
Outputs of similar age from Clinical Cancer Research
#25
of 187 outputs
Altmetric has tracked 33,212,904 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 91st percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 17,326 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.7. This one has done well, scoring higher than 86% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 413,163 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 92% of its contemporaries.
We're also able to compare this research output to 187 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 86% of its contemporaries.
